Cargando…

A multiple sclerosis disease progression measure based on cumulative disability

BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease cour...

Descripción completa

Detalles Bibliográficos
Autores principales: Manouchehrinia, Ali, Kingwell, Elaine, Zhu, Feng, Tremlett, Helen, Hillert, Jan, Ramanujam, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521354/
https://www.ncbi.nlm.nih.gov/pubmed/33487091
http://dx.doi.org/10.1177/1352458520988632
_version_ 1784584882786140160
author Manouchehrinia, Ali
Kingwell, Elaine
Zhu, Feng
Tremlett, Helen
Hillert, Jan
Ramanujam, Ryan
author_facet Manouchehrinia, Ali
Kingwell, Elaine
Zhu, Feng
Tremlett, Helen
Hillert, Jan
Ramanujam, Ryan
author_sort Manouchehrinia, Ali
collection PubMed
description BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease course. METHODS: We developed the nARMSS – normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from −5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. RESULTS: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. CONCLUSION: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible.
format Online
Article
Text
id pubmed-8521354
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85213542021-10-19 A multiple sclerosis disease progression measure based on cumulative disability Manouchehrinia, Ali Kingwell, Elaine Zhu, Feng Tremlett, Helen Hillert, Jan Ramanujam, Ryan Mult Scler Original Research Papers BACKGROUND: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. OBJECTIVE: The objective of this study is to create a severity metric that can reliably summarize a patient’s disease course. METHODS: We developed the nARMSS – normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from −5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. RESULTS: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. CONCLUSION: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible. SAGE Publications 2021-01-25 2021-10 /pmc/articles/PMC8521354/ /pubmed/33487091 http://dx.doi.org/10.1177/1352458520988632 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Papers
Manouchehrinia, Ali
Kingwell, Elaine
Zhu, Feng
Tremlett, Helen
Hillert, Jan
Ramanujam, Ryan
A multiple sclerosis disease progression measure based on cumulative disability
title A multiple sclerosis disease progression measure based on cumulative disability
title_full A multiple sclerosis disease progression measure based on cumulative disability
title_fullStr A multiple sclerosis disease progression measure based on cumulative disability
title_full_unstemmed A multiple sclerosis disease progression measure based on cumulative disability
title_short A multiple sclerosis disease progression measure based on cumulative disability
title_sort multiple sclerosis disease progression measure based on cumulative disability
topic Original Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521354/
https://www.ncbi.nlm.nih.gov/pubmed/33487091
http://dx.doi.org/10.1177/1352458520988632
work_keys_str_mv AT manouchehriniaali amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT kingwellelaine amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT zhufeng amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT tremletthelen amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT hillertjan amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT ramanujamryan amultiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT manouchehriniaali multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT kingwellelaine multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT zhufeng multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT tremletthelen multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT hillertjan multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability
AT ramanujamryan multiplesclerosisdiseaseprogressionmeasurebasedoncumulativedisability